BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
Scientist-led competitive selection deepens BenchSci’s presence in European biopharma TORONTO — BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci’s agentic research environment for preclinical drug discovery, within the organization.…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
